Shantel Holcomb/LinkedIn
Nov 7, 2025, 03:28
Shantel Holcomb: Boston Scientific is Investing in Innovative Solutions to Improve Outcomes for Patients With CAD
Shantel Holcomb, Senior Talent Acquisition Specialist at Boston Scientific, posted on LinkedIn:
“Did you know that coronary artery disease (CAD) is the leading cause of death worldwide? Boston Scientific is investing in innovative solutions to improve outcomes for patients with CAD.”
Read full paper here.
Stay informed with Hemostasis Today.
-
Apr 13, 2026, 06:57Heghine Khachatryan: Why PNH Is More Than a Hemolytic Disease
-
Apr 13, 2026, 05:43Wolfgang Miesbach: A Historic Experiment That Changed Our Understanding of ITP
-
Apr 13, 2026, 04:49Danielle Boyle: This Consultation Is an Opportunity for The Entire ITP Community to Be Heard
-
Apr 13, 2026, 04:18Stephen Cornelissen: You Might Be Eligible to Donate Blood – Here’s Why It’s Worth Checking
-
Apr 13, 2026, 04:12Angie Read: A Powerful Conversation on Survival, Recovery, and Purpose on Stroke Sisters’ Latest Episode
-
Apr 13, 2026, 04:04Ramy Abdelnaby: Telestroke Rounds Show Superior Guideline Adherence in Subacute Care
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management